A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
A phase 1/2 trial of AK109+AK104 in advanced solid tumours, run by Akeso, now recruiting.
Overview
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05142423 by Akeso, with 198 participants planned, started 2021-11-03 and due to reach its primary completion in 2027-04. Interventions recorded: AK109+AK104.
Similar pages
not linked directly; found by shared links- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.